PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Actinium Pharmaceuticals, Inc. (ATNM)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00507W2061
CUSIP00507W206
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$217.39M
EPS-$1.93
Gross Profit (TTM)$1.03M
EBITDA (TTM)-$52.61M
Year Range$4.00 - $9.86
Target Price$25.47
Short %6.57%
Short Ratio7.64

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ATNM

Actinium Pharmaceuticals, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Actinium Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-40.00%-20.00%0.00%20.00%40.00%60.00%NovemberDecember2024FebruaryMarchApril
50.00%
17.14%
ATNM (Actinium Pharmaceuticals, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Actinium Pharmaceuticals, Inc. had a return of 77.17% year-to-date (YTD) and -1.85% in the last 12 months. Over the past 10 years, Actinium Pharmaceuticals, Inc. had an annualized return of -30.78%, while the S&P 500 had an annualized return of 10.79%, indicating that Actinium Pharmaceuticals, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date77.17%7.41%
1 month34.33%-0.81%
6 months51.77%18.38%
1 year-1.85%23.57%
5 years (annualized)-11.11%12.02%
10 years (annualized)-30.78%10.79%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
20245.91%58.55%-8.21%
2023-1.50%-5.74%-17.92%10.92%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ATNM is 50, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.

The Risk-Adjusted Performance Rank of ATNM is 5050
Actinium Pharmaceuticals, Inc.(ATNM)
The Sharpe Ratio Rank of ATNM is 4949Sharpe Ratio Rank
The Sortino Ratio Rank of ATNM is 5252Sortino Ratio Rank
The Omega Ratio Rank of ATNM is 5050Omega Ratio Rank
The Calmar Ratio Rank of ATNM is 4949Calmar Ratio Rank
The Martin Ratio Rank of ATNM is 4848Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Actinium Pharmaceuticals, Inc. (ATNM) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ATNM
Sharpe ratio
The chart of Sharpe ratio for ATNM, currently valued at 0.02, compared to the broader market-2.00-1.000.001.002.003.004.000.02
Sortino ratio
The chart of Sortino ratio for ATNM, currently valued at 0.61, compared to the broader market-4.00-2.000.002.004.006.000.61
Omega ratio
The chart of Omega ratio for ATNM, currently valued at 1.07, compared to the broader market0.501.001.501.07
Calmar ratio
The chart of Calmar ratio for ATNM, currently valued at 0.02, compared to the broader market0.001.002.003.004.005.006.000.02
Martin ratio
The chart of Martin ratio for ATNM, currently valued at 0.05, compared to the broader market0.0010.0020.0030.000.05
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.15, compared to the broader market-2.00-1.000.001.002.003.004.002.15
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.11, compared to the broader market-4.00-2.000.002.004.006.003.11
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.501.001.501.38
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.63, compared to the broader market0.001.002.003.004.005.006.001.63
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.76, compared to the broader market0.0010.0020.0030.008.76

Sharpe Ratio

The current Actinium Pharmaceuticals, Inc. Sharpe ratio is 0.02. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
0.02
2.15
ATNM (Actinium Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Actinium Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-97.72%
-2.49%
ATNM (Actinium Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Actinium Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Actinium Pharmaceuticals, Inc. was 98.98%, occurring on Nov 28, 2023. The portfolio has not yet recovered.

The current Actinium Pharmaceuticals, Inc. drawdown is 97.72%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.98%Apr 24, 20142417Nov 28, 2023
-58.67%Mar 25, 201332May 31, 201394Dec 9, 2013126
-32.13%Dec 11, 20139Dec 23, 201352Mar 12, 201461
-11.51%Mar 26, 20141Mar 26, 20143Mar 31, 20144
-10.7%Apr 4, 20142Apr 7, 201411Apr 23, 201413

Volatility

Volatility Chart

The current Actinium Pharmaceuticals, Inc. volatility is 30.16%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%NovemberDecember2024FebruaryMarchApril
30.16%
3.24%
ATNM (Actinium Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Actinium Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items